GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » GF Score

Adcock Ingram Holdings (JSE:AIP) GF Score : 93/100 (As of Jun. 08, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings GF Score?

Adcock Ingram Holdings has the GF Score of 93, which implies that the company might have Highest outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 9/10
3. Growth Rank : 9/10
4. GF Value Rank : 6/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Adcock Ingram Holdings might have Highest outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Adcock Ingram Holdings's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Adcock Ingram Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adcock Ingram Holdings's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adcock Ingram Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Adcock Ingram Holdings's GF Score falls into.



Adcock Ingram Holdings  (JSE:AIP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Adcock Ingram Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Adcock Ingram Holdings (JSE:AIP) Business Description

Traded in Other Exchanges
N/A
Address
1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.